Showing 1-10 of about 57 articles.
Epizyme, Inc.
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the appointment of Dr. Shefali...
Epizyme, Inc.
CAMBRIDGE, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it plans to report its second...
Epizyme, Inc.
Consistently High Responses in Patients with an EZH2 Activating MutationDurable Clinical Responses and Progression-Free Survival Observed in Patients With or Without an EZH2 Activating MutationCompany...
Epizyme, Inc.
Disease Control Rate of 51 Percent Achieved at 12 WeeksRepresents the First Reported Clinical Data of an EZH2 Inhibitor in Patients with Relapsed/Refractory Malignant Mesothelioma CAMBRIDGE, Mass.,...
Epizyme, Inc.
CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a...
Epizyme, Inc.
CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that new data from two Phase 2 trials...
Epizyme, Inc.
Enrollment of Patients Completed in Multiple Tazemetostat Combination Studies EU Orphan Designations Received for Tazemetostat Conference Call to be Held on May 17, 2018 at 9:30 a.m. ET CAMBRIDGE,...
Epizyme, Inc.
First Quarter 2018 Financial Results to be Announced May 8, 2018 Investor Conference Call to be Scheduled for May 17, 2018 to Discuss Updated Interim Data from Tazemetostat Trials CAMBRIDGE, Mass.,...
Epizyme, Inc.
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that U.S.-based enrollment of new...
Epizyme, Inc.
CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today its first-in-human data on the...
Showing 1-10 of about 57 articles.
